Sector News

Novartis lures John Tsai from Amgen to fill CMO seat

April 19, 2018
Life sciences

Vas Narasimhan, M.D., has persuaded John Tsai, M.D., to fill the vacant CMO role at Novartis. Tsai took up the same position at Amgen just 11 months ago but had his head turned by the digitally-enabled pipeline Narasimhan is building at Novartis.

Narasimhan has moved quickly to make his mark on Novartis since stepping up from CMO to CEO in February, striking an $8.7 billion takeover of gene therapy biotech AveXis and sketching out a vision for how technology will overhaul drug development. But Narasimhan’s vacation of the CMO position left him reliant on temporary cover for a critical role.

Now, Narasimhan has found his CMO. Tsai arrives at Novartis following an 18-year tour of leading biopharma companies. After a six-year stint at Pfizer, Tsai moved to Bristol-Myers Squibb and rose to the position of clinical development and medical head, marketed products. Tsai’s rise caught the attention of Amgen, leading the big biotech to name him CMO in May. But the interest of Novartis has brought Tsai’s stay at the company to a premature end.

Tsai’s résumé ticks many of the boxes all Big Pharmas look for in a CMO—and some that are more specific to Narasimhan’s plans for Novartis.

“His expertise across multiple therapeutic areas, including cardiovascular, oncology and neuroscience combined with his background in electrical engineering will be a source of great strength for Novartis,” Narasimhan said in a statement.

Tsai accrued cardiovascular clinical experience during his time at Pfizer, where he focused on the field and oversaw 26 pivotal studies. The breadth of Tsai’s work expanded at Bristol-Myers. After starting out at Bristol-Myers in his cardiovascular sweet spot, Tsai soon started taking on general medical roles and went on to specialize in oncology for a time.

The appointment allows Rob Kowalski, Ph.D., to relinquish his temporary hold on the CMO role and return his full focus to his responsibilities as head of global regulatory affairs.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.